# Lycia Therapeutics Inc. (LYCA) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $27.60, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Lycia Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 213.3×**. Each dollar of revenue is priced at 213.3×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -3.6%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -591.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -540.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: 32.2%**. 32.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 20.9%**. Return on all capital, debt included, is 20.9%: comfortably above what that capital costs.
- **Return on assets: -37.5%**. Each dollar of assets produces -37.5% of profit.

## Growth
- **Revenue growth (1 yr): -54.9%**. Revenue fell 54.9% over the last year.

## Financial health
- **Net debt / EBITDA: 2.2×**. It would take 2.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 12.43** (quick 12.43). Current assets cover the next year's liabilities 12.43 times.
- **Altman Z-score: 2.10**. A Z-score of 2.10 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Lycia Therapeutics Inc. does not currently pay a dividend, but it returned 0.0% of its market value through buybacks over the last year.

## Price and momentum
- **From 52-week high: -24.4%** (24.4% above the low). Trading 24% below its 52-week high.

Live score and charts: https://foliofundamentals.com/analyzer?s=LYCA · Page: https://foliofundamentals.com/stocks/lyca

Not investment advice.